Generate the best cell lines for complex antibody therapeutics with unrivaled clonality assurance in just days.
Replace 8-12 Weeks of Challenging Well Plate Steps with the Less Than 1 Week Opto™ CLD Workflow on the Beacon® Optofluidic Platform.
Traditional well-plate workflows are slow, laborious and inefficient. The Cell Line Development Workflow on the Beacon platform changes this. You can now select top clones with >99% monoclonality assurance and a superior data package in just days.
Generate the Best Cell Lines
Quantification of thousands of clones over multiple days of on-chip culture enables selection and recovery of clones with 1.5 – 3X higher titers than clones selected by traditional clone-picking technologies after scale-up to shake flask fed-batch cultures.
Complex Antibody Molecules
Select Top Clones for Even Non-Traditional Antibody Molecules
The Opto CLD Workflow selects top clones by measuring growth and titers over multiple days of on-chip culture. SpotLight™ assays enable quantification of both traditional and non-traditional antibodies, such as Fc-engineered mAbs, bispecifics, and multispecifics.
Superior Data Package
Compile a Superior Data Package with Simple, Visual Confirmation of Monoclonality
Unlike traditional well-plate approaches, the Beacon Cell Line Development Workflow provides a visual record of all clones – in an automated fashion – and allows confident assessment of monoclonality. Cells can be visually tracked from the moment they are loaded into NanoPen™ chambers through culture, antibody secretion assays, and eventual recovery of top secreting clones, providing a complete visual record of cell morphology, growth rate, and behavior over days of on-chip culture.
Unrivaled Monoclonality Assurance
Get >99% Monoclonality Assurance with a Single, Automated Round of Cloning